Next Article in Journal
Imaging Plate Autoradiography for Ingested Anthropogenic Cesium-137 in Butterfly Bodies: Implications for the Biological Impacts of the Fukushima Nuclear Accident
Next Article in Special Issue
Real-Life Assessment of the Ability of an Ultraviolet C Lamp (SanificaAria 200, Beghelli) to Inactivate Airborne Microorganisms in a Healthcare Environment
Previous Article in Journal
The Impact of Systemic Oncological Treatments on the Fertility of Adolescents and Young Adults—A Systematic Review
Previous Article in Special Issue
Molecular Characterization of Influenza A/H3N2 Virus Isolated from Indonesian Hajj and Umrah Pilgrims 2013 to 2014
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 13
Issue 5
10.3390/life13051210
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma

by
Usasom Khongsri
1,2,
Peerawit Chongrattanameteekul
1,
Sineenart Chantarachart
2,
Kornravee Photichai
3,
Nittaya Chanayat
3,
Thanya Varinrak
3,
Raktham Mektrirat
1,4,5,* and
Nuttawan Srifawattana
2,*
1
Department of Veterinary Biosciences and Public Health, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
2
Small Animal Hospital, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
3
Center of Veterinary Diagnosis and Technology Transfer, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand
4
Epidemiological and Innovative Research Group for Infectious Diseases, Chiang Mai University, Chiang Mai 50200, Thailand
5
Research Center for Pharmaceutical Nanotechnology, Chiang Mai University, Chiang Mai 50200, Thailand
*
Authors to whom correspondence should be addressed.
Life 2023, 13(5), 1210; https://doi.org/10.3390/life13051210
Submission received: 28 April 2023 / Revised: 9 May 2023 / Accepted: 16 May 2023 / Published: 18 May 2023
(This article belongs to the Special Issue Trends in Microbiology 2024)
Browse Figures
Versions Notes

Abstract

:
The prevalence of methicillin-resistant Staphylococcus pseudintermedius (MRSP) that causes pyoderma has been gradually shifting, according to many surveillance studies, with annual changes. The empirical co-trimoxazole regimen remains interesting, but research on co-trimoxazole susceptibility to MRSP is limited. The objective of this study was to evaluate the susceptibility of co-trimoxazole to canine pyoderma MRSP isolates. Sixty isolates of S. pseudintermedius were identified as 16 MRSP and 44 methicillin-susceptible S. pseudintermedius (MSSP) using an oxacillin disk diffusion test and VITEK 2 system with VITEK GP card. Using the VITEK 2 system with a VITEK AST-GP81 card, the susceptibility rates of MRSP (15.00%) and MSSP (35.00%) to co-trimoxazole was observed. The median MIC of co-trimoxazole on MSSP (median, ≤10; IQR, 10–320) was lower than that of MRSP (median, ≥320; IQR, 10–320) (p = 0.5889, Mann-Whitney test). Percent attainment of PK/PD targets in MRSP (q 12 h, 43.75; q 8 h, 43.75) were lower than that of MSSP (q 12 h, 52.27; q 8 h, 52.27) (p = 0.7710). These findings show the moderately phenotypic co-trimoxazole susceptibilities of both MRSP and MSSP. Further study is required to develop clinical trials examining the use of co-trimoxazole in dogs with pyoderma.

1. Introduction

Canine pyoderma remains one of the most frequently diagnosed skin infections in dogs [1]. An opportunistic gram-positive Staphylococci is thought to be the primary cause of skin infections in companion animals [2]. Staphylococcus pseudintermedius represents the most prevalent cause of canine pyoderma [3]. When infections are not appropriately treated, S. pseudintermedius might become resistant [4,5]. Consequently, several staphylococci from dermatological canine patients frequently exhibit methicillin resistance [6,7,8]. The majority of methicillin resistant isolates develop multidrug resistance (MDR), which is defined as resistance to at least three antimicrobial classes, and severely restricts the therapeutic options available in clinical practice [9,10]. Pan-susceptible strains within any given S. pseudintermedius continue to occur but have become infrequent in clinical practice. The presence of MDR staphylococci, which veterinary practitioners are increasingly encountering, makes managing pyoderma more expensive and challenging [11]. Moreover, the increased occurrence of infections caused by MDR and methicillin-resistant S. pseudintermedius (MRSP) is a public health concern due to the risk of zoonotic diseases in pet owners [12,13,14,15]. In addition, the Infectious Diseases Society of America (IDSA) established recommendations on the treatment for human methicillin-resistant coagulase positive staphylococcal infections, including skin and soft tissue infections, bacteremia, endocarditis, bone and joint infections and infections of central nervous system [16].
Antimicrobial medication, whether topical, systemic, or both, is suggested in all but the mildest cases of canine pyoderma, according to recent evidence-based guidelines [17]. First generation cephalosporins, amoxicillin-clavulanate, clindamycin and potentiated sulfonamides-trimethoprim (or ormetoprim) are the first tier of systemic antimicrobial treatment options for superficial bacterial folliculitis in dogs [18]. Antibiotic therapy for suspected bacterial infections is frequently effective. However, recurrences have been connected to resistance to a range of commonly prescribed antimicrobial drugs including β-lactam antibiotics [19] and clindamycin [20].
Although newer antimicrobial agents have mostly superseded sulfonamides in the treatment of many infections, they remain effective and are the agents of choice in many cases [21]. The bacterial enzyme dihydropteroate synthase, which turns para-aminobenzoic acid into dihydropteroic acid, the direct precursor of folic acid, is inhibited by sulfonamides [22]. Diaminopyrimidines, in combination with sulfonamides, has a synergistic effect by specifically inhibiting microbial dihydrofolate reductase, the enzyme that converts dihydrofolate to tetrahydrofolate. The use of cotrimoxazole (sulfamethoxazole trimethoprim; SXT) for the management of many kinds of infected animals has been well documented. This medication is also relatively affordable and can be utilized to treat a wide range of infections [23]. One such antifolate, cotrimazole, is an efficient antibacterial agent used as a last option to treat infections caused by methicillin-resistant S. aureus (MRSA) [24,25]. Moreover, the community-acquired MRSA is common; oral cotrimazole is a treatment option for skin and soft tissue infections [26]. Many methicillin-resistant Staphylococci (MRS) strains have been approved for cotrimazole treatment in animals [27]. As a consequence, non-β-lactam antimicrobials have become increasingly important.
The antibiograms of S. aureus have been well established in human medicine. Despite this, S. pseudointermedius has received relatively little study attention in veterinary medicine, particularly regarding isolates from canine pyoderma in Thailand. Methicillin-resistant Staphylococcus pseudintermedius is becoming more common. As a result of antimicrobial resistant bacteria, treating skin infections in dogs is getting increasingly difficult. The objectives of this study were to compare antimicrobial susceptibility and distributions of minimum inhibitory concentration (MIC) of cotrimazole in S. pseudintermedius isolated from canine pyoderma, with a special focus on the differences between the isolates of methicillin-resistant S. pseudintermedius (MRSP) and methicillin-susceptible S. pseudintermedius (MSSP). The pharmacokinetic/pharmacodynamic (PK/PD) parameter in predicting the efficacy of cotrimoxazole was also evaluated. These research findings help to better understand antimicrobials for use in canine pyoderma, as well as the develop evidence-based research in veterinary practice. The study will support efforts in the fight against the spread of antimicrobial resistance and the behavioral changes associated with cotrimazole usage.

2. Materials and Methods

2.1. Studied Specimen and Ethical Approval

This prospective study was conducted at the Center of veterinary diagnosis and technology transfer, Faculty of Veterinary Medicine, Chiang Mai University, Thailand. We tested and analyzed a total of sixty sequential, non-duplicate isolates collected from clinical specimens of dogs with pyoderma at a Small Animal Hospital, Faculty of Veterinary Medicine, Chiang Mai University, Thailand between January to December 2022. The research study was ethically approved by the Animal Care and Use Committee, Faculty of Veterinary Medicine, Chiang Mai University (approval number: S3/2563). The Institute Biosafety Committee, Chiang Mai University, also granted permission to test the pathogens (approval number: CMUIBC A-0763011).

2.2. Primary Identification of Coagulase-Positive Staphylococci

All bacterial samples were cultivated using Tryptic soy agar plates (Merck, Darmstadt, Germany) with 5% defibrinated sheep blood, and aerobically incubated at 37 °C for 24 h. The development of presumed staphylococcal colonies was determined by morphological properties including hemolytic characteristics, pigmentation, and typical colony shape. The suspected colonies were sub-cultured onto Mannitol salt agar (Oxoid Ltd., Basingstoke, UK) and incubated aerobically at 37 °C for 24 h. The purified colonies were morphologically identified by gram staining, catalase, oxidase, clumping factor, and tube coagulase tests.

2.3. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing (AST) was performed by the Kirby-Bauer disk diffusion method according to The Clinical and Laboratory Standards Institute (CLSI) standards. The coagulase-positive staphylococcal isolates were inoculated into Bacto™ Todd-Hewitt broth (THB) (Becton Dickinson & Co., Sparks, MD, USA) and incubated aerobically at 37 °C for 24 h. Bacterial culture was adjusted to a concentration of 1.5 × 108 colony-forming units/mL using a McFarland densitometer (Grant Instruments, Cambridgeshire, UK) and swabbed on BBL™ Mueller-Hinton agar plates (Becton Dickinson & Co., Sparks, MD, USA). All isolates were subjected to the AST by the agar diffusion method with two antimicrobial disks including 1 µg oxacillin (OX) and 23.75 µg sulfamethoxazole-1.25 µg trimethoprim. After 24 h incubation at 30 °C, the size of the bacterial growth inhibition zone dimeters (ZD) was interpreted as sensitive (S) (≥16 mm) and resistant (R), including intermediate resistant (11–15 mm) and resistant (≤10 mm), according to the antimicrobial breakpoints for Staphylococci detailed in the CLSI guidelines.

2.4. Confirmation of Staphylococcus pseudintermedius

The presumptive coagulase-positive staphylococcal isolates were then subjected to identification using the VITEK 2 Compact instrument (Biomerieux, Marcy l’Etoile, France) according to the manufacturer’s instructions. The disposable VITEK GP cards were used to identify S. pseudintermedius. The GP identity card is a completely closed system, requiring minimal additional reagents. The card was loaded onto a cassette made specifically for the VITEK 2 system, placed inside the apparatus, automatically placed in a vacuum, protected from the elements, and automatically subjected to colorimetric measurement every 15 min for a maximal incubating period of 8 h. The VITEK 2 database version 9.02 was applied. This database enables bacterial identification in a kinetic mode commencing 180 min after the initial beginning of the incubation process.

2.5. Determination of Minimum Inhibitory Concentration Values

The presumptive isolates of S. pseudintermedius were also subsequently investigated for antimicrobial susceptibility using the VITEK 2 Compact apparatus. The cefoxitin testing for MRSP confirmation and the MICs of cotrimazole among MRSP and MSSP were achieved by using a single disposable VITEK AST-GP81 card per isolate. The AST-GP81 card was automatically inoculated with a bacterial suspension generated in 0.45% sodium chloride solution at a spectrophotometric turbidity of 0.5. Inoculum preparation and card filling were usually separated by less than 30 min and put into the Vitek-2 apparatus for incubation and reading. The Advanced Expert System was used to provide categorical interpretations of the Vitek-2 AST data.

2.6. Target Attainment of Pharmacokinetic and Pharmacodynamics

The pharmacokinetic profile of oral cotrimazole at a dosage of 30 mg/kg for once-daily administration in dogs was utilized [28]. Plasma concentration of cotrimazole above the MIC throughout the whole dosing interval (T0–24 > MIC) was performed for achieving a specific PK/PD criterion. Successful target attainment in more than half of the total dosing intervals qualifies as acceptable overall for reaching the criterion. Probability of target attainment analysis is used to optimize dosing regimens of cotrimazole for patient dogs infected with MRSP and MSSP.

2.7. Statistical Analysis

Descriptive statistics were used to describe data, including frequency, percentage, proportion, range, average with standard deviation, and median with interquartile range to express the basic information on the tested bacteria. The distribution of ZD and MIC values of cotrimazole against bacterial isolates was plotted. The normality of the continuous variable distribution was examined using the Shipiro-Wilk test and normal Q-Q plots. The Mann-Whitney U test was used to assess differences between two independent groups when the dependent variable is ordinal or continuous but not normally distributed. In order to fit the data in the contingency table, the agreement of ZD results of tested isolates against oxacillin and cotrimazole were compared by Cohen’s kappa statistic. The oxacillin and cotrimazole susceptibility were also compared using odd ratios (ORs). Cohen’s kappa and OR statistics were also used to compare the MIC values of tested isolates against cefoxitin and cotrimazole. The median and 90th percentile were also calculated by regression equations. The association between two continuous variables of antimicrobial ZD and MIC values was assessed using Pearson’s correlation coefficients. Percentage probabilities of PK/PD target attainment of cotrimazole in the MRSP and MSSP groups were calculated by time-above-MIC targets. Chi-square tests were used to determine the association between two categorical variables and the difference in proportions. The differences between variables were considered statistically significant when the bicaudal probability was lower than 5% (p < 0.05) due to chance (error type I). Statistical analysis was performed with R statistical software (RStudio, Boston, MA, USA).

3. Results

3.1. Cotrimazole Susceptibility among Coagulase-Positive Staphylococci

Sixty sequential isolates from patient dogs with pyoderma were identified as coagulase-positive staphylococci (CPS) by the conventional method according to CLSI guidelines. Data from the general comparison of the disk diffusion testing results for oxacillin and cotrimazole against all canine pyoderma CPS were demonstrated in Table 1. Among the tested isolates, the percentage of susceptibility to antimicrobials was as follows: 65.00% to oxacillin and 38.33% to cotrimazole [10.00% in oxacillin-resistant isolates (OX-R CPS) and 28.33% in oxacillin-susceptible isolates (OX-S CPS)]. Moreover, the cotrimazole susceptibility was related with a significant increase in chances for OX-S CPS isolates [odd ratio (OR), 1.90; 95% confidence interval (CI), 0.65–6.47] compared to OX-R CPS isolates (p = 0.2538). However, slight agreement between both antimicrobial agents was detected in 32 isolates (53.33% of the observations) with kappa coefficients 0.13 [95%CI, −0.09–0.34; standard error (SE) of kappa 0.11]. By the point of interception, the distribution of cotrimazole ZD on CPS isolates was described in Table 2 and Figure 1a. The ZD range (0–28 mm) and mean ± SD (10.15 ± 11.13) of cotrimazole among total CPS isolates was found. Interestingly, the median ZD of cotrimazole on OX-R CPS [median, 0; interquartile range (IQR), 0–19] was narrower than that of OX-S CPS (median, 15; IQR, 0–24) (p = 0.1631, Mann-Whitney test). Moreover, both OX-R CPS and OX-S CPS groups exhibited susceptibility to cotrimazole; they were 28.57% and 56.41, respectively (Figure 1b).

3.2. Cotrimazole Susceptibility among Pathogenic S. pseudintermedius

Sixty presumptive CPS isolates from dogs with pyoderma were confirmed as S. pseudintermedius by the VITEK 2 Compact instrument with VITEK GP cards. For cefoxitin testing, sixteen MRSP isolates were confirmed, whereas the remaining 44 MSSP isolates were identified. The MICs of cotrimazole in MRSP and MSSP were also achieved by using the VITEK AST-GP81 cards. The MICs and ZDs of oxacillin against tested S. pseudintermedius were well-correlated (correlation coefficient −0.9622, p < 0.01). The significant negative association for the MICs and ZDs of cotrimazole on S. pseudintermedius with correlation coefficient −0.9193 was also observed (p < 0.01) (Figure 2).
The general information gleaned from the comparison of the MIC values for oxacillin and cotrimazole against sixty canine pyoderma S. pseudintermedius isolates was demonstrated in Table 3. The proportion of antimicrobial susceptibility among the tested isolates was 73.33% to cefoxitin surrogate marker and 50.00% to cotrimazole (15.00% in MRSP and 35.00% in MSSP). Moreover, the cotrimazole susceptibility showed a significant increase in chances for MSSP isolates (OR, 0.71; 95%CI, 0.23–2.40) compared to MRSP isolates (p = 0.5593). Interestingly, the susceptible rate of cotrimazole in the MRSP group was 56.25% (Figure 3b). In addition, the fair agreement between both antimicrobial agents was 28 isolates (46.67% of the observations) with kappa coefficients −0.067 (95%CI, −0.290–0.157; SE of kappa 0.11). The distribution of cotrimazole MIC on S. pseudintermedius isolates was described in Table 4 and Figure 3a. The median MIC of cotrimazole on MSSP (median, ≤10; IQR, 10–320) was lower than that of MRSP (median, ≥320; IQR, 10–320) (p = 0.5889, Mann-Whitney test). Moreover, the MIC90: MIC50 ratio of cotrimazole on MSSP (320/10) was also significantly lower than that of MRSP (320/320).

3.3. PK-PD Target Achieving of Cotrimazole on Pathogenic S. pseudintermedius

Cotrimazole achievement rates relating to S. pseudintermedius were evaluated based on the time the free drug stayed over the plasma MIC between treatment intervals (Table 5). The PK parameters of cotrimazole in dogs orally administered (30 mg/kg/24 h) were used. The result demonstrated that percentages of time above MIC on 24-, 12- and 8-h dosing intervals were 33.33, 66.66 and 100.00, respectively. With a 24-h dosing interval, both the MRSP and the MSSP had zero percentage probabilities of achieving the PK/PD target. Percent attainment of PK/PD targets in MRSP (q 12 h, 43.75; q 8 h, 43.75) were lower than that of MSSP (q 12 h, 52.27; q 8 h, 52.27) (p = 0.7710).

4. Discussion

The genus Staphylococcus is common in epidermal and nasal flora and leads to opportunity-based infections in both humans and animals. When compared to coagulase-negative staphylococci, CPS may result in more severe infections [29,30]. A great many prior investigations have demonstrated that S. pseudintermedius is a prevalent cause of canine pyoderma [29,31,32]. In a recent investigation, all examined isolates were conventionally identified as CPS. All CPS-tested isolates were indeed subsequently confirmed as S. pseudintermedius using the VITEK 2 Compact instrument and VITEK GP cards. This actively demonstrates that all pathogenic bacteria from clinical specimens of dogs with pyoderma were consistent with the previous studies. The range of concentrations determined by the Vitek-2 AST-GP card is in accordance with veterinary breakpoints established according to the current CLSI guidelines for the oxacillin utilized in this investigation [33].
The particular reason for using the VITEK 2 GP test technique was validated in accordance with the Association of Official Analytical Collaboration (AOAC) recommendations for the identification of Staphylococcus species usingthe Performance Tested MethodSM (PTM) and Official Methods of AnalysisSM (OMA). Furthermore, a previous research investigation indicated that the Vitek 2 Compact instrument accurately identifies 123 (93.2%; n = 132) different Staphylococcus strains from the database species. In addition, the research points out the remarkable accomplishment of the colorimetric Vitek 2 GP card, which is capable of being utilized in medical, veterinary, agricultural, and food laboratories [34]. As a consequence of this, previous research has recommended that the VITEK 2 GP test card method be used as the Official First Action for the detection of certain Gram-positive bacteria [35]. Moreover, the accuracy of VITEK-2 for phenotypic identification of Staphylococci is higher than that of the MicroScan and Crystal GP systems [36]. Through the use of molecular techniques, genotypic bacterial species might be reliably detected. Unfortunately, 16s rDNA sequencing did not confirm all bacterial isolates in this study.
The susceptibility of all CPS Isolates to cotrimazole was determined by AST using an OX disk. In accordance with EUCAST recommendations, oxacillin has been used as a surrogate for methicillin-resistant AST. The oxacillin disk (1 g) accurately predicted mecA-mediated methicillin resistance in S. pseudintermedius. [37,38]. Likewise, this study revealed that one-third of tested CPS (21 isolates) were OX-R CPS. Furthermore, 16 MRSP isolates were identified by the cefoxitin testing on OX-R CPS isolates using VITEK AST-GP81 cards. Previous investigations have demonstrated the correlation of cefoxitin and oxacillin ZD and MIC values with mecA/mecC PCR and the diagnostic test accuracy of disk diffusion relative to broth microdilution for canine clinical S. pseudintermedius [39]. Moreover, the Vitek 2 automated system also provides a highly reliable approach for detecting Staphylococcal mecA and mecC positive isolates [40,41,42]. This actively demonstrates that the five remaining isolates that showed oxacillin resistance but not the cefoxitin resistance phenotype, were classified as MSSP. However, 1.1% of methicillin-resistant Staphylococci probably remain sensitive to cefoxitin, according to a prior study [43].
In this study, the cotrimazole susceptibility among the tested S. pseudintermedius was 50.00% with the 50th percentile of the MIC less than 10 mg/L. The finding is consistent with previous research on the susceptibility of S. pseudintermedius isolated from infected dogs to cotrimazole [44,45,46]. Moreover, many previous studies demonstrated that the median MIC was less than 10 mg/L [47,48,49]. Surprisingly, this research also demonstrated that the cotrimazole sensitivity of the OX-R CPS and MRSP groups was 28.57% and 56.25%, respectively. These findings differed from the previous study in that MRSP was completely resistant to cotrimazole [50]. However, the MIC50/MIC90 ratio of cotrimazole on MSSP was much lower than that of MRSP. In addition, cotrimazole demonstrated a low MIC range for MRSP, and both MIC90 and MIC50 of MRSP were above the break point. These results suggest that MRSP developed resistance to cotrimazole at a higher rate than MSSP. We are aware of some limitations in our study. MIC values were determined using automated testing procedures rather than broth microdilution. The methicillin-resistance of bacterial strains is caused by the mec gene, which encodes a second penicillin binding protein with a low affinity for all β-lactam antibiotics [51]. Consequently, a group of antimetabolite sulfonamide has been less affected by mec gene mutation. However, Staphylococcus isolates may mutate a DfrB gene causing bacteria resistance if they are exposed to cotrimazole for a duration longer than two weeks [52].
Disk diffusion and broth microdilution methods have been approved as AST reference procedures by the CLSI and the EUCAST. The automated approaches are preferred to manual labor methods. The Vitek-2 system has been attached to the Advanced Expert System, which was developed to evaluate Vitek-2 results on the basis of specific bacterial species. AST reliability of Vitek-2 has been validated for numerous bacterial species of Staphylococci and Enterococci [53]. However, when testing antimicrobial agents against particular staphylococci, Vitek-2 might provide the results that are not accurate [54]. However, this present study revealed a strong correlation between ZD and MIC values of both oxacillin and cotrimazole against S. pseudintermedius; hence, ZD might be used to predict MIC values. These findings are in agreement with previously published research that reported almost perfect agreement between disk diffusion to Vitek-2 of oxacillin and cotrimazole against S. pseudintermedius isolates collected in clinical microbiology laboratories in Italy during 2018 to 2020 [55].
For surface and superficial conditions, topical therapy should be the only on-animal antimicrobial treatment administered. However, systemic treatment is suggested for deep pyoderma, multifocal or severe superficial infections in dogs that are not susceptible to topical therapy. This recommendation, which was reached through consensus among the Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Disease (ISCAID), focuses on the treatment of superficial bacterial folliculitis in particular and classifies antimicrobial agents into first- and second-tier categories [56]. In addition, the MIC value is necessary for antimicrobial treatment regimens that predict outcomes. Interestingly, this PK/PD target of cotrimazole might be reached with approximately 50% of both MRSP and MSSP. However, the pharmacodynamic parameter for optimizing the dose of cotrimazole is limited [57]. Cotrimazole has time-dependent bacteriostatic activity and the potential for concentration-dependent bactericidal activity against particular species [58]. The pharmacokinetic of cotrimazole in dogs has been also infrequently documented. As a result, achievement rates of cotrimazole to S. pseudintermedius were estimated based on the duration that the free drug remained over the plasma MIC between dosing intervals. The effectiveness of systemic antimicrobial medication for both MRSP and MSSP infections is primarily influenced by bacterial susceptibility. Moreover, it also depends on other criteria of rational drug use, including drug administration, correct dosing, and dog’s owner compliance [59]. Systemic therapy combined with topical antibiotic treatment is advised wherever possible to minimize contamination of the environmental microorganism and the likelihood of spreading the infection to other hosts, as well as to potentially decrease the total duration of systemic prescription.
Multi-center surveillance studies showed progressive shifts with annual trends of antimicrobial susceptibility [60]. The development of evidence-based research in veterinary medicine is essential since occurrences of pyoderma-causing MRSP have been reported [61,62]. Empirical antimicrobial agent selection is no longer reliable for pyoderma therapy in locations with high MRSP prevalence. The empirical amoxicillin-clavulanate and first-generation cephalosporins have a poor effectiveness for superficial bacterial folliculitis in dogs. Therefore, the treatment of canine pyoderma is becoming more challenging due to bacteria like MRSP. The outcomes showed that the remaining empirical cotrimazole regimen is an attractive alternative for the MRSP canine pyoderma. Future susceptibility tests should focus on S. pseudintermedius isolated from different geographic regions, time dynamics, and with an increased variety of antimicrobials susceptibility patterns.

5. Conclusions

The results highlighted the first study on cotrimazole susceptibility and PK/PD target attainment in pathogenic S. pseudintermedius isolated from dogs with pyoderma. Through this research, different levels of phenotypic cotrimazole susceptibility of MRSP and MSSP was observed. Interestingly, when given cotrimazole at at least a 12-h dosing interval, the attainment rate of pathogenic MRSP was more than 50%. Further studies are necessary to expand the clinical trial of cotrimazole in dogs with pyoderma.

Author Contributions

Project administration, R.M. and N.S.; funding acquisition, N.S.; resources and supervision, R.M.; Conceptualization and methodology, U.K., R.M. and N.S.; investigation, U.K., S.C., K.P., N.C., T.V., R.M. and N.S.; software, validation and formal analysis, data curation, visualization and writing—original draft preparation P.C. and R.M.; writing—review and editing, U.K., P.C., S.C., K.P., N.C., T.V., R.M. and N.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research was partially funded by Faculty of Veterinary Medicine, Chiang Mai University, grant number R000028480.

Institutional Review Board Statement

The study was conducted according to the approval Animal Care and Use Committee, Faculty of Veterinary Medicine, Chiang Mai University (approval number: S3/2563). The Institute Biosafety Committee, Chiang Mai University, also granted permission to test the pathogens (approval number: CMUIBC A-0763011).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting this study are available from the corresponding author upon reasonable request.

Acknowledgments

This research was partially supported by Chiang Mai University. The authors are thankful for the Research Center of Pharmaceutical Nanotechnology Research and Epidemiological and Innovative Research Group for Infectious Diseases, Chiang Mai University. for the facility and instrument support.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gortel, K. Recognizing pyoderma: More difficult than it may seem. Vet. Clin. North Am. Small Anim. Pract. 2013, 43, 1–18. [Google Scholar] [CrossRef] [PubMed]
  2. Nocera, F.P.; Ambrosio, M.; Fiorito, F.; Cortese, L.; De Martino, L. On Gram-Positive- and Gram-Negative-Bacteria-Associated Canine and Feline Skin Infections: A 4-Year Retrospective Study of the University Veterinary Microbiology Diagnostic Laboratory of Naples, Italy. Animals 2021, 11, 1603. [Google Scholar] [CrossRef] [PubMed]
  3. Bannoehr, J.; Guardabassi, L. Staphylococcus pseudintermedius in the dog: Taxonomy, diagnostics, ecology, epidemiology and pathogenicity. Vet. Dermatol. 2012, 23, 253–266, e51–e52. [Google Scholar] [CrossRef] [PubMed]
  4. Weese, J.S.; Giguere, S.; Guardabassi, L.; Morley, P.S.; Papich, M.; Ricciuto, D.R.; Sykes, J.E. ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. J. Vet. Intern. Med. 2015, 29, 487–498. [Google Scholar] [CrossRef]
  5. Gronthal, T.; Eklund, M.; Thomson, K.; Piiparinen, H.; Sironen, T.; Rantala, M. Antimicrobial resistance in Staphylococcus pseudintermedius and the molecular epidemiology of methicillin-resistant S. pseudintermedius in small animals in Finland. J. Antimicrob. Chemother. 2017, 72, 1021–1030. [Google Scholar] [CrossRef] [Green Version]
  6. Platenik, M.O.; Archer, L.; Kher, L.; Santoro, D. Prevalence of mecA, mecC and Panton-Valentine-Leukocidin Genes in Clinical Isolates of Coagulase Positive Staphylococci from Dermatological Canine Patients. Microorganisms 2022, 10, 2239. [Google Scholar] [CrossRef]
  7. Gonzalez-Dominguez, M.S.; Carvajal, H.D.; Calle-Echeverri, D.A.; Chinchilla-Cardenas, D. Molecular Detection and Characterization of the mecA and nuc Genes from Staphylococcus Species (S. aureus, S. pseudintermedius, and S. schleiferi) Isolated from Dogs Suffering Superficial Pyoderma and Their Antimicrobial Resistance Profiles. Front. Vet. Sci. 2020, 7, 376. [Google Scholar] [CrossRef]
  8. Chanayat, Y.; Akatvipat, A.; Bender, J.B.; Punyapornwithaya, V.; Meeyam, T.; Anukool, U.; Pichpol, D. The SCCmec Types and Antimicrobial Resistance among Methicillin-Resistant Staphylococcus Species Isolated from Dogs with Superficial Pyoderma. Vet. Sci. 2021, 8, 85. [Google Scholar] [CrossRef]
  9. Janos, D.; Viorel, H.; Ionica, I.; Corina, P.; Tiana, F.; Roxana, D. Carriage of Multidrug Resistance Staphylococci in Shelter Dogs in Timisoara, Romania. Antibiotics 2021, 10, 801. [Google Scholar] [CrossRef]
  10. McCarthy, A.J.; Harrison, E.M.; Stanczak-Mrozek, K.; Leggett, B.; Waller, A.; Holmes, M.A.; Lloyd, D.H.; Lindsay, J.A.; Loeffler, A. Genomic insights into the rapid emergence and evolution of MDR in Staphylococcus pseudintermedius. J. Antimicrob. Chemother. 2015, 70, 997–1007. [Google Scholar] [CrossRef] [Green Version]
  11. Jones, R.D.; Kania, S.A.; Rohrbach, B.W.; Frank, L.A.; Bemis, D.A. Prevalence of oxacillin- and multidrug-resistant staphylococci in clinical samples from dogs: 1772 samples (2001–2005). J. Am. Vet. Med. Assoc. 2007, 230, 221–227. [Google Scholar] [CrossRef] [PubMed]
  12. Somayaji, R.; Priyantha, M.A.; Rubin, J.E.; Church, D. Human infections due to Staphylococcus pseudintermedius, an emerging zoonosis of canine origin: Report of 24 cases. Diagn. Microbiol. Infect. Dis. 2016, 85, 471–476. [Google Scholar] [CrossRef] [PubMed]
  13. Lai, C.H.; Ma, Y.C.; Shia, W.Y.; Hsieh, Y.L.; Wang, C.M. Risk Factors for Antimicrobial Resistance of Staphylococcus Species Isolated from Dogs with Superficial Pyoderma and Their Owners. Vet. Sci. 2022, 9, 306. [Google Scholar] [CrossRef] [PubMed]
  14. Carroll, K.C.; Burnham, C.D.; Westblade, L.F. From canines to humans: Clinical importance of Staphylococcus pseudintermedius. PLoS Pathog. 2021, 17, e1009961. [Google Scholar] [CrossRef] [PubMed]
  15. Bhooshan, S.; Negi, V.; Khatri, P.K. Staphylococcus pseudintermedius: An undocumented, emerging pathogen in humans. GMS Hyg. Infect. Control 2020, 15, Doc32. [Google Scholar] [CrossRef]
  16. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin. Infect. Dis. 2011, 52, 285–292. [Google Scholar] [CrossRef]
  17. Jackson, H.A.; Marsella, R. Manual of Canine and Feline Dermatology, 3rd ed.; British Small Animal Veterinary Association ProQuest Ebook Central: Quedgeley, Gloucester, UK; Ann Arbor, MI, USA, 2012. [Google Scholar]
  18. Morris, D.O.; Loeffler, A.; Davis, M.F.; Guardabassi, L.; Weese, J.S. Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: Diagnosis, therapeutic considerations and preventative measures: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Vet. Dermatol. 2017, 28, 304-e69. [Google Scholar] [CrossRef] [Green Version]
  19. Yoo, J.H.; Yoon, J.W.; Lee, S.Y.; Park, H.M. High prevalence of Fluoroquinolone- and Methicillin-resistant Staphylococcus pseudintermedius isolates from canine pyoderma and otitis externa in veterinary teaching hospital. J. Microbiol. Biotechnol. 2010, 20, 798–802. [Google Scholar]
  20. Faires, M.C.; Gard, S.; Aucoin, D.; Weese, J.S. Inducible clindamycin-resistance in methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus pseudintermedius isolates from dogs and cats. Vet. Microbiol. 2009, 139, 419–420. [Google Scholar] [CrossRef]
  21. Batra, P.; Deo, V.; Mathur, P.; Gupta, A.K. Cotrimoxazole, a wonder drug in the era of multiresistance: Case report and review of literature. J. Lab. Physicians 2017, 9, 210–213. [Google Scholar] [CrossRef]
  22. MacDougall, C. Sulfonamides, Trimethoprim-Sulfamethoxazole, Quinolones, and Agents for Urinary Tract Infections. In Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e; Brunton, L.L., Hilal-Dandan, R., Knollmann, B.C., Eds.; McGraw-Hill Education: New York, NY, USA, 2017. [Google Scholar]
  23. Prescott, J.F. Sulfonamides, Diaminopyrimidines, and Their Combinations. In Antimicrobial Therapy in Veterinary Medicine; Giguère, S., Prescott, J.F., Dowling, P.M., Eds.; John Wiley & Sons: Ames, IA, USA, 2013; pp. 279–294. [Google Scholar] [CrossRef]
  24. Brown, N.M.; Brown, E.M.; Guideline Development, G. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): Updated guidelines from the UK. J. Antimicrob. Chemother. 2021, 76, 1377–1378. [Google Scholar] [CrossRef] [PubMed]
  25. Goldberg, E.; Paul, M.; Talker, O.; Samra, Z.; Raskin, M.; Hazzan, R.; Leibovici, L.; Bishara, J. Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: A retrospective cohort study. J. Antimicrob. Chemother. 2010, 65, 1779–1783. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Bowen, A.C.; Carapetis, J.R.; Currie, B.J.; Fowler, V., Jr.; Chambers, H.F.; Tong, S.Y.C. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infect. Dis. 2017, 4, ofx232. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Plumb, D.C. Plumb's Veterinary Drug Handbook, 9th ed.; PharmaVet Inc. John Wiley & Sons, Inc.: Stockholm, Sweden, WI, USA; Hoboken, NJ, USA, 2018; p. 1428. [Google Scholar]
  28. Ling, G.V.; Rohrich, P.J.; Ruby, A.L.; Johnson, D.L.; Jang, S.S. Canine urinary tract infections: A comparison of in vitro antimicrobial susceptibility test results and response to oral therapy with ampicillin or with trimethoprim-sulfa. J. Am. Vet. Med. Assoc. 1984, 185, 277–281. [Google Scholar]
  29. Shevchenko, M.; Savcheniuk, M.; Yarchuk, B.; Sakhniuk, N.; Tsarenko, T. Coagulase-positive staphylococci in dogs and their antimicrobial resistance (systematic review). Nauk. Vìsn. Vet. Med. 2021, 1, 104–118. [Google Scholar] [CrossRef]
  30. Morris, D.O.; Rook, K.A.; Shofer, F.S.; Rankin, S.C. Screening of Staphylococcus aureus, Staphylococcus intermedius, and Staphylococcus schleiferi isolates obtained from small companion animals for antimicrobial resistance: A retrospective review of 749 isolates (2003-04). Vet. Dermatol. 2006, 17, 332–337. [Google Scholar] [CrossRef]
  31. Rana, E.A.; Islam, M.Z.; Das, T.; Dutta, A.; Ahad, A.; Biswas, P.K.; Barua, H. Prevalence of coagulase-positive methicillin-resistant Staphylococcus aureus and Staphylococcus pseudintermedius in dogs in Bangladesh. Vet. Med. Sci. 2022, 8, 498–508. [Google Scholar] [CrossRef]
  32. Joffe, D.; Goulding, F.; Langelier, K.; Magyar, G.; McCurdy, L.; Milstein, M.; Nielsen, K.; Villemaire, S. Prevalence of methicillin-resistant staphylococci in canine pyoderma cases in primary care veterinary practices in Canada: A preliminary study. Can. Vet. J. 2015, 56, 1084–1086. [Google Scholar]
  33. CLSI. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, 4th ed.; CLSI Supplement VET08; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2018. [Google Scholar]
  34. Delmas, J.; Chacornac, J.P.; Robin, F.; Giammarinaro, P.; Talon, R.; Bonnet, R. Evaluation of the Vitek 2 system with a variety of Staphylococcus species. J. Clin. Microbiol. 2008, 46, 311–313. [Google Scholar] [CrossRef] [Green Version]
  35. Crowley, E.; Bird, P.; Fisher, K.; Goetz, K.; Boyle, M.; Benzinger, M.J., Jr.; Juenger, M.; Agin, J.; Goins, D.; Johnson, R.L. Evaluation of the VITEK 2 gram positive (GP) microbial identification test card: Collaborative study. J. AOAC Int. 2012, 95, 1425–1432. [Google Scholar] [CrossRef]
  36. Kim, M.; Heo, S.R.; Choi, S.H.; Kwon, H.; Park, J.S.; Seong, M.W.; Lee, D.H.; Park, K.U.; Song, J.; Kim, E.C. Comparison of the MicroScan, VITEK 2, and Crystal GP with 16S rRNA sequencing and MicroSeq 500 v2.0 analysis for coagulase-negative Staphylococci. BMC Microbiol. 2008, 8, 233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Skov, R.; Varga, A.; Matuschek, E.; Ahman, J.; Bemis, D.; Bengtsson, B.; Sunde, M.; Humphries, R.; Westblade, L.; Guardabassi, L.; et al. EUCAST disc diffusion criteria for the detection of mecA-Mediated beta-lactam resistance in Staphylococcus pseudintermedius: Oxacillin versus cefoxitin. Clin. Microbiol. Infect. 2020, 26, 122.e1–122.e6. [Google Scholar] [CrossRef] [PubMed]
  38. Wu, M.T.; Burnham, C.A.; Westblade, L.F.; Dien Bard, J.; Lawhon, S.D.; Wallace, M.A.; Stanley, T.; Burd, E.; Hindler, J.; Humphries, R.M. Evaluation of Oxacillin and Cefoxitin Disk and MIC Breakpoints for Prediction of Methicillin Resistance in Human and Veterinary Isolates of Staphylococcus intermedius Group. J. Clin. Microbiol. 2016, 54, 535–542. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Badger, S.; Abraham, S.; O'Dea, M.; Saputra, S.; Abraham, R.J.; Worthing, K.A.; Norris, J.M.; Trott, D.J.; Jordan, D.; Caraguel, C.G.B. Diagnostic accuracy of phenotypic assays for determining antimicrobial resistance status in Staphylococcus pseudintermedius isolates from canine clinical cases. Vet. Microbiol. 2019, 234, 101–109. [Google Scholar] [CrossRef]
  40. Fernandes, C.J.; Fernandes, L.A.; Collignon, P.; Australian Group on Antimicrobial, R. Cefoxitin resistance as a surrogate marker for the detection of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2005, 55, 506–510. [Google Scholar] [CrossRef] [Green Version]
  41. Roisin, S.; Nonhoff, C.; Denis, O.; Struelens, M.J. Evaluation of new Vitek 2 card and disk diffusion method for determining susceptibility of Staphylococcus aureus to oxacillin. J. Clin. Microbiol. 2008, 46, 2525–2528. [Google Scholar] [CrossRef] [Green Version]
  42. Junkins, A.D.; Lockhart, S.R.; Heilmann, K.P.; Dohrn, C.L.; Von Stein, D.L.; Winokur, P.L.; Doern, G.V.; Richter, S.S. BD Phoenix and Vitek 2 detection of mecA-mediated resistance in Staphylococcus aureus with cefoxitin. J. Clin. Microbiol. 2009, 47, 2879–2882. [Google Scholar] [CrossRef] [Green Version]
  43. Cartwright, E.J.; Paterson, G.K.; Raven, K.E.; Harrison, E.M.; Gouliouris, T.; Kearns, A.; Pichon, B.; Edwards, G.; Skov, R.L.; Larsen, A.R.; et al. Use of Vitek 2 antimicrobial susceptibility profile to identify mecC in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 2013, 51, 2732–2734. [Google Scholar] [CrossRef] [Green Version]
  44. Scherer, C.B.; Botoni, L.S.; Coura, F.M.; Silva, R.O.; Santos, R.D.d.; Heinemann, M.B.; Costa-Val, A.P. Frequency and antimicrobial susceptibility of Staphylococcus pseudintermedius in dogs with otitis externa. Ciência Rural 2018, 48. [Google Scholar] [CrossRef] [Green Version]
  45. Viegas, F.M.; Santana, J.A.; Silva, B.A.; Xavier, R.G.C.; Bonisson, C.T.; Camara, J.L.S.; Renno, M.C.; Cunha, J.L.R.; Figueiredo, H.C.P.; Lobato, F.C.F.; et al. Occurrence and characterization of methicillin-resistant Staphylococcus spp. in diseased dogs in Brazil. PLoS ONE 2022, 17, e0269422. [Google Scholar] [CrossRef]
  46. Lord, J.; Millis, N.; Jones, R.D.; Johnson, B.; Kania, S.A.; Odoi, A. Patterns of antimicrobial, multidrug and methicillin resistance among Staphylococcus spp. isolated from canine specimens submitted to a diagnostic laboratory in Tennessee, USA: A descriptive study. BMC Vet. Res. 2022, 18, 91. [Google Scholar] [CrossRef] [PubMed]
  47. Saputra, S.; Jordan, D.; Worthing, K.A.; Norris, J.M.; Wong, H.S.; Abraham, R.; Trott, D.J.; Abraham, S. Antimicrobial resistance in coagulase-positive staphylococci isolated from companion animals in Australia: A one year study. PLoS ONE 2017, 12, e0176379. [Google Scholar] [CrossRef] [Green Version]
  48. Priyantha, R.; Gaunt, M.C.; Rubin, J.E. Antimicrobial susceptibility of Staphylococcus pseudintermedius colonizing healthy dogs in Saskatoon, Canada. Can. Vet. J. 2016, 57, 65–69. [Google Scholar] [PubMed]
  49. Humphries, R.M.; Wu, M.T.; Westblade, L.F.; Robertson, A.E.; Burnham, C.A.; Wallace, M.A.; Burd, E.M.; Lawhon, S.; Hindler, J.A. In Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin. J. Clin. Microbiol. 2016, 54, 1391–1394. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Maluping, R.P.; Paul, N.C.; Moodley, A. Antimicrobial susceptibility of methicillin-resistant Staphylococcus pseudintermedius isolated from veterinary clinical cases in the UK. Br. J. Biomed. Sci. 2014, 71, 55–57. [Google Scholar] [CrossRef] [PubMed]
  51. Mlynarczyk-Bonikowska, B.; Kowalewski, C.; Krolak-Ulinska, A.; Marusza, W. Molecular Mechanisms of Drug Resistance in Staphylococcus aureus. Int. J. Mol. Sci. 2022, 23, 88. [Google Scholar] [CrossRef] [PubMed]
  52. Sato, T.; Ito, R.; Kawamura, M.; Fujimura, S. The Risk of Emerging Resistance to Trimethoprim/Sulfamethoxazole in Staphylococcus aureus. Infect. Drug Resist. 2022, 15, 4779–4784. [Google Scholar] [CrossRef]
  53. Bobenchik, A.M.; Hindler, J.A.; Giltner, C.L.; Saeki, S.; Humphries, R.M. Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp. J. Clin. Microbiol. 2014, 52, 392–397. [Google Scholar] [CrossRef] [Green Version]
  54. Buchan, B.W.; Anderson, N.W.; Ledeboer, N.A. Comparison of BD Phoenix and bioMerieux Vitek 2 automated systems for the detection of macrolide-lincosamide-streptogramin B resistance among clinical isolates of Staphylococcus. Diagn. Microbiol. Infect. Dis. 2012, 72, 291–294. [Google Scholar] [CrossRef]
  55. Rampacci, E.; Trotta, M.; Fani, C.; Silvestri, S.; Stefanetti, V.; Brachelente, C.; Mencacci, A.; Passamonti, F. Comparative Performances of Vitek-2, Disk Diffusion, and Broth Microdilution for Antimicrobial Susceptibility Testing of Canine Staphylococcus pseudintermedius. J. Clin. Microbiol. 2021, 59, e0034921. [Google Scholar] [CrossRef]
  56. Hillier, A.; Lloyd, D.H.; Weese, J.S.; Blondeau, J.M.; Boothe, D.; Breitschwerdt, E.; Guardabassi, L.; Papich, M.G.; Rankin, S.; Turnidge, J.D.; et al. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet. Dermatol. 2014, 25, 163-e43. [Google Scholar] [CrossRef] [PubMed]
  57. Eyler, R.F.; Shvets, K. Clinical Pharmacology of Antibiotics. Clin. J. Am. Soc. Nephrol. 2019, 14, 1080–1090. [Google Scholar] [CrossRef] [Green Version]
  58. Brown, G.R. Cotrimoxazole—Optimal dosing in the critically ill. Ann. Intensive Care 2014, 4, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Summers, J.F.; Brodbelt, D.C.; Forsythe, P.J.; Loeffler, A.; Hendricks, A. The effectiveness of systemic antimicrobial treatment in canine superficial and deep pyoderma: A systematic review. Vet. Dermatol. 2012, 23, 305–329, e61. [Google Scholar] [CrossRef]
  60. Diaz, R.; Afreixo, V.; Ramalheira, E.; Rodrigues, C.; Gago, B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin. Microbiol. Infect. 2018, 24, 97–104. [Google Scholar] [CrossRef] [Green Version]
  61. Pires Dos Santos, T.; Damborg, P.; Moodley, A.; Guardabassi, L. Systematic Review on Global Epidemiology of Methicillin-Resistant Staphylococcus pseudintermedius: Inference of Population Structure from Multilocus Sequence Typing Data. Front. Microbiol. 2016, 7, 1599. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Loeffler, A.; Lloyd, D.H. What has changed in canine pyoderma? A narrative review. Vet. J. 2018, 235, 73–82. [Google Scholar] [CrossRef] [Green Version]
Life 13 01210 g001 550
Figure 1. Comparison of inhibition zone diameter of cotrimazole between oxacillin-resistant coagulase-positive Staphylococci (OX-R CPS) and oxacillin-susceptible Staphylococci (OX-S CPS). (a) Bar graph compared the distributions of cotrimazole’s inhibition zone diameters between OX-R CPS (black bar) and OX-S CPS (white bar). Susceptible (green dash line) and resistant (red dash line) breakpoints recommended from CLSI guidelines (b) The point and connecting line graph showed the proportion of resistant (SXT-R CPS; dark green) and susceptible (SXT-S CPS; light green) to cotrimazole in OX-R CPS and OX-S CPS groups. The chi-square was used for statistical analysis and calculating p-values.
Figure 1. Comparison of inhibition zone diameter of cotrimazole between oxacillin-resistant coagulase-positive Staphylococci (OX-R CPS) and oxacillin-susceptible Staphylococci (OX-S CPS). (a) Bar graph compared the distributions of cotrimazole’s inhibition zone diameters between OX-R CPS (black bar) and OX-S CPS (white bar). Susceptible (green dash line) and resistant (red dash line) breakpoints recommended from CLSI guidelines (b) The point and connecting line graph showed the proportion of resistant (SXT-R CPS; dark green) and susceptible (SXT-S CPS; light green) to cotrimazole in OX-R CPS and OX-S CPS groups. The chi-square was used for statistical analysis and calculating p-values.
Life 13 01210 g001
Life 13 01210 g002 550
Figure 2. The correlation of MIC values and the inhibition zone diameters against 60 isolates of S. pseudintermedius. (a) Scatter diagram of oxacillin MIC and inhibition zone diameter with a data trend line. (b) Scatter diagram of cotrimazole MIC and inhibition zone diameter with a data trend line. The Pearson correlation was used for statistical analysis.
Figure 2. The correlation of MIC values and the inhibition zone diameters against 60 isolates of S. pseudintermedius. (a) Scatter diagram of oxacillin MIC and inhibition zone diameter with a data trend line. (b) Scatter diagram of cotrimazole MIC and inhibition zone diameter with a data trend line. The Pearson correlation was used for statistical analysis.
Life 13 01210 g002
Life 13 01210 g003 550
Figure 3. Comparison of minimum inhibitory concentration of cotrimazole between methicillin-resistant S. pseudintermedius (MRSP) and methicillin-susceptible S. pseudintermedius (MSSP). (a) Bar graph compared the distributions of cotrimazole’s minimum inhibitory concentration between MRSP (black bar) and MSSP (white bar). Susceptible (green dash line) and resistant (red dash line) breakpoints recommended by CLSI guidelines (b) The point and connecting line graph showed the proportion of resistant (SXT-R SP; dark green) and susceptible (SXT-S SP; light green) to cotrimazole in MRSP and MSSP groups. The chi-square was used for statistical analysis and calculating p-values.
Figure 3. Comparison of minimum inhibitory concentration of cotrimazole between methicillin-resistant S. pseudintermedius (MRSP) and methicillin-susceptible S. pseudintermedius (MSSP). (a) Bar graph compared the distributions of cotrimazole’s minimum inhibitory concentration between MRSP (black bar) and MSSP (white bar). Susceptible (green dash line) and resistant (red dash line) breakpoints recommended by CLSI guidelines (b) The point and connecting line graph showed the proportion of resistant (SXT-R SP; dark green) and susceptible (SXT-S SP; light green) to cotrimazole in MRSP and MSSP groups. The chi-square was used for statistical analysis and calculating p-values.
Life 13 01210 g003
Table
Table 1. Comparison of phenotypic susceptibility for cotrimazole of oxacillin-resistant and susceptible Coagulase-Positive Staphylococci.
Table 1. Comparison of phenotypic susceptibility for cotrimazole of oxacillin-resistant and susceptible Coagulase-Positive Staphylococci.
SXT-R CPSSXT-S CPSTotal
OX-R CPS15621
OX-S CPS221739
Total372360
OX-R CPS; oxacillin-resistant coagulase-positive Staphylococci. OX-S CPS; oxacillin-susceptible coagulase-positive Staphylococci. SXT-R CPS; cotrimazole-resistant coagulase-positive Staphylococci. SXT-S CPS; cotrimazole-susceptible coagulase-positive Staphylococci.
Table
Table 2. Descriptive statistics of inhibition zone diameter (mm) using cotrimazole disk diffusion against 21 oxacillin-resistant and 39 susceptible coagulase-positive Staphylococci isolates.
Table 2. Descriptive statistics of inhibition zone diameter (mm) using cotrimazole disk diffusion against 21 oxacillin-resistant and 39 susceptible coagulase-positive Staphylococci isolates.
SusceptibilityPathogenic Bacteria
OX-R CPSOX-S CPSTotal
Range0–240–280–28
Mean ± SD7.71 ns ± 9.6911.46 ns ± 11.7510.15 ± 11.13
Median (IQR)0 ns (0–19)15 ns (0–24)0 (0–22)
OX-R CPS; oxacillin-resistant coagulase-positive Staphylococci. OX-S CPS; oxacillin-susceptible coagulase-positive Staphylococci. ns; Not Significant (Mann-Whitney test; p > 0.05).
Table
Table 3. Comparison of phenotypic susceptibility for cotrimazole of methicillin-resistant and susceptible S. pseudintermedius.
Table 3. Comparison of phenotypic susceptibility for cotrimazole of methicillin-resistant and susceptible S. pseudintermedius.
SXT-R SPSXT-S SPTotal
MRSP7916
MSSP232144
Total303060
MRSP; Methicillin-resistant S. pseudintermedius. MSSP; Methicillin-susceptible S. pseudintermedius. SXT-R SP; Cotrimazole-resistant S. pseudintermedius. SXT-S SP; Cotrimazole-susceptible S. pseudintermedius.
Table
Table 4. Descriptive statistics of minimum inhibitory concentration (mg/L) of cotrimazole against 16 methicillin-resistant and 44 susceptible S. pseudintermedius using the VITEK 2 Compact instrument with VITEK AST-GP81 cards.
Table 4. Descriptive statistics of minimum inhibitory concentration (mg/L) of cotrimazole against 16 methicillin-resistant and 44 susceptible S. pseudintermedius using the VITEK 2 Compact instrument with VITEK AST-GP81 cards.
SusceptibilityPathogenic Bacteria
MRSPMSSPTotal
Median (IQR)≥320 ns (10–320)≤10 ns (10–320)≤10 (10–320)
50th percentile≥320≤10≤10
90th percentile≥320≥320≥320
MIC90: MIC5013232
MRSP; Methicillin-resistant S. pseudintermedius. MSSP; Methicillin-susceptible S. pseudintermedius. ns = Not Significant.
Table
Table 5. Percentage probabilities of pharmacokinetic and pharmacodynamics target attainment of oral cotrimazole with reference dose 30 mg/kg for each frequency regimens based on the evaluation of plasma concentration time above MIC targets in dogs.
Table 5. Percentage probabilities of pharmacokinetic and pharmacodynamics target attainment of oral cotrimazole with reference dose 30 mg/kg for each frequency regimens based on the evaluation of plasma concentration time above MIC targets in dogs.
Dosing Interval%Time above MICAttainment (%)
MRSPMSSPp-Value
q 24 h33.330.000.00>0.9999
q 12 h66.6643.7552.270.7710
q 8 h100.0043.7552.270.7710
MRSP; Methicillin-resistant S. pseudintermedius. MSSP; Methicillin-susceptible S. pseudintermedius. q; every (quaque).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Khongsri, U.; Chongrattanameteekul, P.; Chantarachart, S.; Photichai, K.; Chanayat, N.; Varinrak, T.; Mektrirat, R.; Srifawattana, N. Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma. Life 2023, 13, 1210. https://doi.org/10.3390/life13051210

AMA Style

Khongsri U, Chongrattanameteekul P, Chantarachart S, Photichai K, Chanayat N, Varinrak T, Mektrirat R, Srifawattana N. Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma. Life. 2023; 13(5):1210. https://doi.org/10.3390/life13051210

Chicago/Turabian Style

Khongsri, Usasom, Peerawit Chongrattanameteekul, Sineenart Chantarachart, Kornravee Photichai, Nittaya Chanayat, Thanya Varinrak, Raktham Mektrirat, and Nuttawan Srifawattana. 2023. "Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma" Life 13, no. 5: 1210. https://doi.org/10.3390/life13051210

APA Style

Khongsri, U., Chongrattanameteekul, P., Chantarachart, S., Photichai, K., Chanayat, N., Varinrak, T., Mektrirat, R., & Srifawattana, N. (2023). Comparative Susceptibility of Pathogenic Methicillin-Resistant and Methicillin-Susceptible Staphylococcus pseudintermedius to Empirical Co-Trimoxazole for Canine Pyoderma. Life, 13(5), 1210. https://doi.org/10.3390/life13051210

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop